> Some doctors have said they won’t prescribe the drug if it does reach the market, because of the mixed data package supporting the company’s application. > S

> Some doctors have said they won’t prescribe the drug if it does reach the market, because of the mixed data package supporting the company’s application. > Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged the data isn’t perfect. However, they contend it could help some patients with Alzheimer’s, a progressive and debilitating disease. Not a shining endorsement of the drug’s efficacy, however I do hope it helps.